Sun Pharma: An update on generic Protonix® litigation

Sun Pharmaceutical Industries Ltd. 17/B, Mahal Industrial Estate, Mahakali Caves Road, Andheri (East), Mumbai 400 093 India Tel.: (91-22) 6645 5645 Fax.: (91-22) 6645 5685 Registered Office : SPARC, Tandalja, Vadodara – 390 020. India Corporate Office : Acme Plaza, Andheri – Kurla Road, Andheri (East), Mumbai – 400 059. India FOR IMMEDIATE RELEASE Sun Pharma: An update on generic Protonix® litigation Mumbai, February 15, 2012: Sun Pharmaceutical Industries Ltd (“Sun Pharma”, also together with its subsidiaries) announces that in the ongoing litigation pending in the United States District Court of District of New Jersey (“the District Court”) regarding Sun Pharma subsidiary’s and Teva’s (“defendants”) generic pantoprazole products, Wyeth has submitted to the District Court confidential expert reports claiming damages against defendants arising out of defendants earlier at-risk launches. Earlier in 2010, the District Court had denied defendants motion for judgment as a matter of law seeking to reverse the jury verdict that the patent is not invalid. The District Court is yet to rule on patent misuse. Wyeth’s experts have estimated the purported damages from Sun Pharma to be $ 960 million. Wyeth’s experts have also claimed Teva may be liable for some of Sun Pharma's damages and vice versa. In due course, Sun Pharma will also serve upon the parties Sun Pharma’s expert reports providing its own assessment on the purported damages. After this, patent misuse and appropriate level of damages will be determined. Sun Pharma believes that it has sound reasons to disagree with these overstated claims of Wyeth, and also continues to believe that the patent is invalid and unenforceable and will pursue all available legal remedies including appeals. Protonix® is a registered trademark of Wyeth Pharmaceuticals, Inc. About Sun Pharma Established in 1983, listed since 1994 and headquartered in In dia, Sun Pharma (Reuters: SUN.BO, Bloomberg: SUNP IN, NSE:SUNPHARMA, BSE: 524715) is an inte rnational, integrated, speciality pharmaceutical company. It manufactures and markets a large basket of pharmaceutical formulations as brande d generics as well as generics in India, US and several other markets across the world. In India, the company is a leader in niche therapy areas of psychiatry, neurology, cardiology, diabetology, gastroenterology, orthopedics and ophthalmolog y. The company has strong skills in product development, process chemistry, and manufacturing of complex API, as well as dosage forms. More information about the company can be found at www.sunpharma.com. Contacts Uday Baldota Mira Desai Tel +91 22 6645 5645, Xtn 605 Tel +91 22 6645 5645, Xtn 606 Tel Direct +91 22 66455605 Tel Direct +91 22 66455606 Mobile +91 98670 10529 Mobile +91 98219 23797 E mail [email protected] E mail [email protected]

The release as fetched from its publisher. sunpharma.com ↗